Venn Life Sciences (VENN) Shares Up 16%

Venn Life Sciences Holdings PLC (LON:VENN) shares rose 16% during mid-day trading on Thursday . The stock traded as high as GBX 3.20 ($0.04) and last traded at GBX 3.08 ($0.04). Approximately 734,605 shares were traded during trading, an increase of 2,271% from the average daily volume of 30,982 shares. The stock had previously closed at GBX 2.65 ($0.03).

In related news, insider Michael (Mike) Ryan sold 138,672 shares of the company’s stock in a transaction dated Friday, December 21st. The shares were sold at an average price of GBX 2 ($0.03), for a total value of £2,773.44 ($3,623.99).

TRADEMARK VIOLATION NOTICE: “Venn Life Sciences (VENN) Shares Up 16%” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://dakotafinancialnews.com/2019/02/23/venn-life-sciences-venn-shares-up-16.html.

Venn Life Sciences Company Profile (LON:VENN)

Venn Life Sciences Holdings Plc, a clinical research organization, provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device companies in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. The company offers drug development planning and strategy services, including clinical feasibility assessment, project management, and in-licensing and technical due diligence; and early drug development services, such as drug candidate selection, CMC, non-clinical/pre-clinical development, clinical pharmacology, pharmacokinetics, and pharmacometrics and PK-PD modelling.

See Also: Consumer behavior in bull markets

Receive News & Ratings for Venn Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venn Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply